ArticleFrontiers in oncology2026
Baseline serum cortisol as a prognostic biomarker for immune checkpoint inhibitor therapy in advanced gastric cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced gastric cancer (AGC), but only a subset of patients benefit. Validated prognostic biomarkers for ICI efficacy in AGC remain limited, and the role of endogenous cortisol-an immunosuppressive steroid hormone-in modulating ICI response is unclear. Methods: This single-center retrospective study enrolled 134 AGC patients who received anti-PD-1 antibody therapy at the Fourth Hospital of Hebei Medical University between January 2019 and September 2023. Baseline serum cortisol and adrenocorticotropic hormone (ACTH) levels were measured via electrochemiluminescence immunoassay. Patients were stratified into low- and high-cortisol groups using a cutoff of 193.95 nmol/L. The primary/secondary endpoints were progression-free survival (PFS), overall survival (OS), and objective response rate (ORR); disease control rate (DCR) was also analyzed. Survival analyses were performed using Kaplan-Meier curves (log-rank test) and Cox proportional hazards models. Results: The entire cohort had a median PFS of 7.0 months (95% CI: 5.44-8.63) and median OS of 14.5 months (95% CI: 13.59-15.34), with an ORR of 15.7% (95% CI: 9.4-21.9%) and DCR of 79.1% (95% CI: 72.1-86.1%). Baseline serum cortisol showed an AUC of 0.673 (95% CI: 0.58-0.77) for OS prediction with a cutoff of 193.95 nmol/L, while ACTH had an AUC of 0.561 (95% CI: 0.46-0.66) at 25.09 pg/mL. Compared with the high-cortisol group, the low-cortisol group had a significantly higher DCR (93.9% vs. 74.3%, P = 0.016), longer median PFS (10.3 vs. 5.7 months, P = 0.047), and longer median OS (17.4 vs. 13.4 months, P = 0.014). Multivariate analysis confirmed high baseline cortisol as an independent prognostic factor for poorer OS (HR=2.03, 95% CI: 1.20-4.00, P = 0.035) and showed a trend toward significance for shorter PFS (HR=1.64, 95% CI: 1.00-2.69, P = 0.050). In subgroup analysis of 112 microsatellite stability (MSS)/microsatellite instability-low (MSI-L) patients, high cortisol remained independently associated with shorter PFS (HR=1.77, 95% CI: 1.02-3.06, P = 0.042). Conclusions: Baseline serum cortisol levels are significantly associated with ICI efficacy in AGC patients, with high baseline cortisol correlating with poorer DCR, PFS, and OS. This study identifies baseline serum cortisol as a promising prognostic biomarker for ICI response in AGC, supporting further exploration of stress hormone signaling in immunotherapy optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.